English Español

[redacted]

See Who May Qualify | Menu

Are you looking for a new clinical trial option for **PCNSL**?

If you are living with primary central nervous system lymphoma (PCNSL), you may be eligible to participate in [redacted]

See who may qualify

Learn more about [redacted]

[redacted] at a Glance

If you have PCNSL, you may be eligible to participate in this clinical study. Complete the questionnaire below to see if you may be eligible to participate.

Learn more about [redacted] →

See Who May Qualify

**Indicates required field.*

Step 1 of 4

By answering the following questions, you agree to have your information retained for the duration of the study, and you will be contacted by phone or email (as provided) regarding your interest in study participation only

Do you want to proceed?*

- (●) Yes
- ( ) No

I am completing this questionnaire on behalf of:*

- ( ) Myself
- ( ) Someone I care for (in the following questions, you/your will reflect the person you care for)

What is your zip code?*

We need to gather this information in order to determine the research site closest to you.

e.g., 12345

What is your date of birth?*

MM/DD/YYYY

Continue

This website uses Secure Socket Layer technology and encryption methods to protect personal health information. If you'd like to know more about this, read the privacy policy.

[redacted]

See Who May Qualify | About [redacted] | About PCNSL | FAQ

Privacy Policy | Your Privacy Choices

[redacted]

About [redacted]

[redacted] is evaluating an investigational study drug in adults with primary central nervous system lymphoma (PCNSL). The study is looking at whether the drug has a favorable safety profile, stops disease progression, and helps those whose disease has returned after response to treatment (relapsed) or has not improved with prior treatment or came back rapidly after initially responding (refractory).

Who Can Participate?

To participate, you must:

- Be at least 18 years of age
- Have a diagnosis of B-cell PCNSL that has come back after treatment (relapsed) or has not improved with prior treatment or came back rapidly after initially responding (refractory)
- Have undergone at least one previous therapy for PCNSL

Additional requirements will apply. The clinical research study team will discuss these with you.

Questions to ask your doctor

Study Participation

The length of participation in [redacted] will be different for each person. Throughout the study, participants will be closely monitored and will visit the research site regularly for assessments, procedures, and health checks. The number of cycles will vary per person, depending on what study drug is assigned and how they respond.

This study is made up of the following three periods:

Screening (up to 4 weeks)

A study doctor will evaluate interested individuals to find out if the clinical research study is a good match. Individuals will first need to give their consent, or permission, to join the study by reading and signing the informed consent form.

Investigational Treatment (28-day cycles)

Study participants will be randomly assigned to receive either the investigational study drug or a standard PCNSL treatment. They will visit the study site one to two times per cycle for study assessments and to receive their assigned study drug.

Follow-up (ongoing)

Participants will return to the study site so that the study team can continue to monitor their health after they have stopped receiving their assigned study drug. There will be one study site visit 28 days after the last study drug dose and then one study visit every eight weeks as long as your cancer remains controlled. There will be a phone call with the study site staff once every three months for health checks.

See who may qualify

About the Study Drug

[redacted] is being done to research an investigational study drug called [redacted] It is an oral (taken by mouth) tablet taken once a day and is thought to disrupt a biological reaction in the malfunctioning lymphocytes (cancerous cells) to potentially prevent them from growing and spreading.

In this study, [redacted] is being compared to a standard PCNSL study drug called R-TMZ, a combination therapy of rituximab (intravenous [IV] infusion) and temozolomide (oral capsule). By doing this, researchers will have something to directly compare the investigational study drug to. This is necessary in clinical research, as it will help make the study results as accurate as possible.

No-Cost Study Drug and Support

All participants in this study will receive either the investigational study drug or the standard study drug at no cost. Support for study-related travel expenses may be available. All study site visits and procedures associated with the study will also be provided at no cost to you or your insurance, as applicable.

About PCNSL

Primary central nervous system lymphoma, or PCNSL, is a rare form of primary central nervous system cancer, accounting for only 2%–3% of cases. It occurs when certain immune cells, called lymphocytes, behave abnormally in the brain, eyes, or spinal cord and form tumors. This can cause many symptoms, including headaches, nausea, vomiting, cognitive deficits, personality changes, behavioral changes, vision problems, digestive issues, and limb pain or weakness.

Currently, there is no drug therapy specifically approved to treat PCNSL in the US or Europe. The treatments that are used instead may be effective at first, but many individuals experience challenging side effects, and the disease often comes back or does not respond to the treatment.

[redacted] is researching an investigational study drug. It is designed to address PCNSL specifically, and researchers are evaluating if the investigational study drug may help stop disease progression and learning about its safety.

See who may qualify

Learn more about [redacted] →

Reference:

1. rarediseases.org/rare-diseases/primary-central-nervous-system-lymphoma

Frequently Asked Questions (FAQs)

Before enrolling in [redacted] you may have questions regarding clinical research studies, the length of the study, and if you may leave the study at any time. If you end up qualifying for the study, you may ask questions to the study team at any time during your involvement in this study.

What Is a Clinical Research Study?

Clinical research studies, also called clinical trials, look at an investigational drug or medical device to see if it is safe, how it works in the body, and if it works to treat a specific disease. Clinical research studies are conducted by doctors who are responsible for the study participants' study-related care. Without clinical trials and volunteer study participants, there would be no new medications.

In most countries, the regulatory health authority, such as the Food and Drug Administration (FDA) in the United States, requires that several phases of clinical research be performed to better understand the safety and effectiveness of new investigational drugs and certain medical devices.

Clinical research studies must be reviewed by an institutional review board (IRB) or ethics committee (EC). An IRB/EC is a group that is responsible for helping to protect the rights and well-being of study participants. In addition, every study participant is monitored with study-related medical tests and exams before, during, and sometimes even after the study.

Can I Leave the Study?

Participation in any clinical research study is completely voluntary, and participants may choose to leave the study at any time for any reason. If you would like to leave the study, you should discuss this with your study doctor, who will give you information about how to do this safely.

What Are the Steps Before I Join?

Before you can take part in the [redacted] clinical research study, you will first need to attend the screening visit(s) for initial tests and assessments to see if you are eligible to participate. After all necessary tests and assessments have been completed, and if you are eligible to participate, you may enter the study and receive the study drug.

Questions to ask your doctor

See who may qualify | Learn more about [redacted] →